- Home
- SHMD vs BCYC Comparison
SHMD vs BCYC Comparison
Compare SHMD & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHMD | BCYC |
|---|---|---|
| Founded | 1864 | 2009 |
| Country | Germany | United Kingdom |
| Employees | 734 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.1M | 296.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SHMD | BCYC |
|---|---|---|
| Price | $4.80 | $4.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.90 |
| AVG Volume (30 Days) | ★ 960.1K | 657.5K |
| Earning Date | 05-15-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $3.92 |
| 52 Week High | $10.65 | $9.18 |
Technical Indicators
Market Signals| Indicator | SHMD | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 36.15 | 61.13 |
| Support Level | $3.82 | $4.25 |
| Resistance Level | $7.20 | $4.75 |
| Average True Range (ATR) | 0.57 | 0.17 |
| MACD | -0.10 | 0.07 |
| Stochastic Oscillator | 0.20 | 91.60 |
Price Performance
Historical ComparisonAbout SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.